Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WSN-OVA is a recombinant strain of the Influenza A virus (specifically the A/WSN/33 strain, H1N1) engineered to express the chicken ovalbumin (OVA) protein or its immunodominant CD8+ T cell epitope, SIINFEKL. It is a widely utilized research tool in immunology, serving as a model pathogen to study the kinetics, differentiation, and exhaustion of T cell responses in mouse models. By infecting mice with WSN-OVA, researchers can track the response of OT-I T cells (transgenic CD8+ T cells specific for the OVA epitope) to an acute viral infection. In the provided context, WSN-OVA is used as a control for acute viral infection to identify miRNA signatures that distinguish effector T cells from exhausted T cells found in chronic infection or tumor environments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WSN-OVA.